Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm

References

• Dendreon Corporation. Sipuleucel-T prescribing information. 2014. Available at: http://www.valeant.com/Portals/25/Pdf/PI/Provenge-PI.pdf
   Google Scholar
• Markowicz S, Engleman EG. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 1990; 85:955-61; PMID:2179270; http://dx.doi.org/10.1172/JCI114525
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-903; PMID:11099318
   PubMed Web of Science ®Google Scholar
• Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, Whitmore JB, Trager JB, Poehlein CH, Frohlich MW et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013; 62:137-47; PMID:22865266; http://dx.doi.org/10.1007/s00262-012-1317-2
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52-8; PMID:8564842; http://dx.doi.org/10.1038/nm0196-52
   Web of Science ®Google Scholar
• Lam KW, Li CY, Yam LT, Sun T, Lee G, Ziesmer S. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 1989; 15:13-21; PMID:2477829; http://dx.doi.org/10.1002/pros.2990150103
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-94; PMID:16809734; http://dx.doi.org/10.1200/JCO.2005.04.5252
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-9; PMID:19536890; http://dx.doi.org/10.1002/cncr.24429
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Dawson NA, Gardner T, Klotz L, Curti BD, Flanigan RC, Fishman MN, Xu Y, Whitmore JB, Frohlich MW. Persistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studies. J Clin Oncol 2010; 28 (Suppl. 15): Abstract 4551; PMID:20547989
   PubMed Web of Science ®Google Scholar
• Beer TM, Glode M, Lance R, Greengold R, Haynes H, Sims R, Wang Y, Sheikh N, Corman J. P10-1, an open-label, multicenter study of sipuleucel-T in men with metastatic castrate-resistant prostate cancer (mCRPC) previously treated with sipuleucel-T: analysis of immunological data. Eur J Cancer 2013; 49 (Suppl. 2): Abstract 2909
   Google Scholar
• McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who received sipuleucel-T. Cancer Immunol Res 2014; 2:988-99; PMID:25189164; http://dx.doi.org/10.1158/2326-6066.CIR-14-0073
   PubMed Web of Science ®Google Scholar
• Fong L, Carroll P, Weinberg VK, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 2014; 106:pii: dju268; PMID:25255802; http://dx.doi.org/10.1093/jnci/dju268
   Google Scholar
• Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011; 17:3884-91; PMID:21680544; http://dx.doi.org/10.1158/1078-0432.CCR-10-2656
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011; 18:e150-7; PMID:21655153; http://dx.doi.org/10.3747/co.v18i3.783
   PubMed Web of Science ®Google Scholar
• Madan RA, Schwaab T, Gulley JL. Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. J Natl Compr Canc Netw 2012; 10:1505-12; PMID:23221788
   PubMed Web of Science ®Google Scholar
• Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599-613; PMID:22395641; http://dx.doi.org/10.1093/jnci/djs033
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Gulley JL. Therapeutic vaccines: the ultimate personalized therapy? Hum Vaccin Immunother. 2013; 9:219-21; PMID:22995839; http://dx.doi.org/10.4161/hv.22106
   PubMed Web of Science ®Google Scholar
• Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011; 17:4558-67; PMID:21558406; http://dx.doi.org/10.1158/1078-0432.CCR-10-3223
   PubMed Web of Science ®Google Scholar
• Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis 2014; 17:259-64; PMID:24957547; http://dx.doi.org/10.1038/pcan.2014.21
   PubMed Web of Science ®Google Scholar
• Federal Drugs Administration Center for Biologics Evaluation & Research. Report on sipuleucel-T. US Food and Drug Administration 2009. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm214540.pdf
   Google Scholar
• Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett 2007; 108:45-51; PMID:17129612; http://dx.doi.org/10.1016/j.imlet.2006.10.009
   PubMed Web of Science ®Google Scholar
• Sprent J, Cho JH, Boyman O, Surh CD. T cell homeostasis. Immunol Cell Biol 2008; 86:312-9; PMID:18362947; http://dx.doi.org/10.1038/icb.2008.12
   PubMed Web of Science ®Google Scholar
• Strasser EF, Zimmermann R, Weisbach V, Ringwald J, Zingsem J, Eckstein R. Mononuclear cell variability and recruitment in non-cytokine-stimulated donors after serial 10-liter leukapheresis procedures. Transfusion 2005; 45:445-52; PMID:15752165; http://dx.doi.org/10.1111/j.1537-2995.2005.04202.x
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Polcari AJ, Shore ND, Price TH, Sims RB, Maher JC, Whitmore JB, Corman JM. An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer. J Urol 2013; 189:521-6; PMID:23253957; http://dx.doi.org/10.1016/j.juro.2012.09.029
   PubMed Web of Science ®Google Scholar
• Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol 2011; 186:877-81; PMID:21788048; http://dx.doi.org/10.1016/j.juro.2011.04.070
   PubMed Web of Science ®Google Scholar
• Gulley JL, Leitman SF, Dahut W, Schlom J. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104:1106; author reply 1109–12; PMID:22825555; http://dx.doi.org/10.1093/jnci/djs280
   PubMed Web of Science ®Google Scholar
• Kolf CM, Bolan CD, Wesley RA, Browning JN, Leitman SF. Sustained decreases in lymphocyte counts in serial long-term leukapheresis donors. Transfusion 2003; 43:(Suppl.) 28A-9A
   Google Scholar
• Ratts RB, Weng NP. Homeostasis of lymphocytes and monocytes in frequent blood donors. Front Immunol 2012; 3:271; PMID:22936935; http://dx.doi.org/10.3389/fimmu.2012.00271
   PubMed Web of Science ®Google Scholar
• McLeod BC, Sniecinski I, Ciavarella D, Owen H, Price TH, Randels MJ, Smith JW. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 1999; 39:282-8; PMID:10204591; http://dx.doi.org/10.1046/j.1537-2995.1999.39399219285.x
   PubMed Web of Science ®Google Scholar
• Strauss RG. Effects on donors of repeated leukocyte losses during plateletpheresis. J Clin Apher 1994; 9:130-4; PMID:7798161; http://dx.doi.org/10.1002/jca.2920090208
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Dunne J, Steele D, McPhail S, Sklar S, Algom D, Richter MA, Rock G. Immune function in blood donors following short-term lymphocytapheresis. Vox Sang 1985; 49:101-9; PMID:4036082; http://dx.doi.org/10.1111/j.1423-0410.1985.tb00776.x
   PubMed Web of Science ®Google Scholar
• Gulley JL, Marté J, Heery CR, Madan RA, Steinberg SM, Leitman SF, Tsang KY, Schlom J. The impact of leukapheresis on immune cell function in patients with advanced cancer. Cancer Immunol Immunother 2015; 64:1429-35; PMID:26243387; http://dx.doi.org/10.1007/s00262-015-1738-9
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaparring P, Piulats JM, Ng S. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138-48; PMID:23228172; http://dx.doi.org/10.1056/NEJMoa1209096
   PubMed Web of Science ®Google Scholar
• de Bono J, Logothetis C, Molin A, Fizazi K, North S, Chu L, Chi K, Jones RJ, Goodman OB, Saad F et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005; PMID:21612468; http://dx.doi.org/10.1056/NEJMoa1014618
   PubMed Web of Science ®Google Scholar
• Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C, Iversen P, Bhattacharya S, Carles J, Chowdhury S et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371:424-33; PMID:24881730; http://dx.doi.org/10.1056/NEJMoa1405095
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-97; PMID:22894553; http://dx.doi.org/10.1056/NEJMoa1207506
   PubMed Web of Science ®Google Scholar
• de Bono J, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376:1147-54; PMID:20888992; http://dx.doi.org/10.1016/S0140-6736(10)61389-X
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, Helle S, O'Sullivan J, Fossa S, Chodacki A, Wiechno P, Logue J, Seke M et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213-23; PMID:23863050; http://dx.doi.org/10.1056/NEJMoa1213755
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-74; PMID:19890632; http://dx.doi.org/10.1007/s00262-009-0782-8
   PubMed Web of Science ®Google Scholar
• Sheikh NA, Small EJ, Quinn DI, Higano CS, Lin DW, Wesley JD, Haynes H, Stewart FP, Poehlein CH, Trager JB. Sipuleucel-T product characterization across different disease states of prostate cancer. J Clin Oncol 2012; 30 (Suppl. 5): Abstract 42
   Web of Science ®Google Scholar
• Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013; 81:1297-302; PMID:23582482; http://dx.doi.org/10.1016/j.urology.2013.01.061
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242-5; PMID:18182665; http://dx.doi.org/10.1200/JCO.2007.12.4008
   PubMed Web of Science ®Google Scholar
• Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N et al. A randomized phase II trial of sipuleucel-T with concurrent vs sequential abiraterone acetate plus prednisone in metastatic castration resistant prostate cancer. Clin Cancer Res 2015; 21:3862-9; PMID:25925891; http://dx.doi.org/10.1158/1078-0432.CCR-15-0079
   Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines: Prostate Cancer. V1.2015. National Cancer Network website. www.nccn.org. Accessed September 22, 2015.
   Google Scholar
• de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14:6302-9; PMID:18829513; http://dx.doi.org/10.1158/1078-0432.CCR-08-0872
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resisant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011; 29:3695-704; PMID:21859988; http://dx.doi.org/10.1200/JCO.2011.35.8648
   PubMed Web of Science ®Google Scholar
• Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013; 23:573-81; PMID:23680145; http://dx.doi.org/10.1016/j.ccr.2013.04.017
   PubMed Web of Science ®Google Scholar
• Alix-Panabières C, Pantel K. Challenges in circulating tumor cell (CTC) research. Nat Rev Cancer 2014; 14:623-31; PMID:25154812; http://dx.doi.org/10.1038/nrc3820
   PubMed Web of Science ®Google Scholar